Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
PRCC
REST API REST API
Homo sapiens
PRCC is differentially expressed in 218 experiments: 91 organism parts: placenta, liver, ... (89 more);, 131 disease states: normal, acute promyelocytic leukemia, ... (129 more);, 60 cell types 247 cell lines 29 compound treatments and 62 other conditions.
Synonyms RCCP1
Orthologs Prcc (Rattus norvegicus)   Prcc (Mus musculus)   PRCC (Gallus gallus)   prcc (Danio rerio)   Q1RML0_BOVIN (Bos taurus)   CG17249 (Drosophila melanogaster)   prcc (Xenopus laevis)   PRCC (Canis familiaris)   (Compare orthologs)
Gene Ontology Term protein binding, cell cycle, nucleus, mitotic cell cycle checkpoint
InterPro Term PRCC_C
UniProt Accession Q92733, Q5SZ05, A6NG79, E9PGC6
Gene-Disease Assocation RENAL CELL CARCINOMA, PAPILLARY, 1; RCCP1
Search EB-eye ENSG00000143294
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-MTAB-24, E-MTAB-25, ... (23 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, E-GEOD-19397, ... (29 experiments)

Factor Value U/D Experiments
SW480
3
E-MEXP-1014, E-MTAB-37, E-GEOD-18005
HCC1937
2
E-MTAB-37, E-MTAB-62
primary culture
2
E-GEOD-2450, E-GEOD-1657
MCF-7
2
E-GEOD-20081, E-GEOD-3529
A459
1
E-GEOD-17347
SW48
1
E-MTAB-37
241 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-GEOD-13987, E-GEOD-11755, ... (28 experiments)

Factor Value U/D Experiments
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
lung carcinoma
1
E-GEOD-17347
resting natural killer cell
1
E-TABM-702
intraepithelial cytotoxic T lymphocyte
1
E-GEOD-4592
osteoblast
1
E-MEXP-1216
LCC
1
E-GEOD-19188
54 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-MEXP-2069, E-MTAB-62, E-MEXP-66, ... (41 experiments)

Factor Value U/D Experiments
multiple myeloma
2
E-GEOD-6691, E-MTAB-62
cervical carcinoma
2
E-MTAB-62, E-MEXP-1331
lung adenocarcinoma
2
E-GEOD-2514, E-MEXP-231
neuroblastoma
2
E-MTAB-37, E-MTAB-62
papillary thyroid carcinoma
1
E-GEOD-3467
mock infected
1
E-MEXP-1072
125 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-6907, E-GEOD-5824, E-GEOD-6462, E-MEXP-1958, ... (19 experiments)

Factor Value U/D Experiments
none
3
4
E-GEOD-5824, E-GEOD-412, E-MEXP-1958, E-GEOD-995, E-GEOD-2649, ... (7 experiments)
sapphyrin PCI-2050
1
E-GEOD-6400
interferon alpha
1
E-GEOD-1740
unknown
1
E-GEOD-7307
4-hydroxytamoxifen
1
1
E-MEXP-2241
ethanol
1
E-MEXP-2241
23 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical info
studied in E-MTAB-37, E-GEOD-17189, E-GEOD-6710, E-GEOD-19348, E-GEOD-1563, ... (8 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-1614, E-GEOD-4667, E-MTAB-62

Disease staging
studied in E-GEOD-19743, E-TABM-147, E-GEOD-19665

Environmental stress
studied in E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-MTAB-73, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847

Genotype
studied in E-MEXP-1437, E-GEOD-17476, E-GEOD-21750, E-GEOD-2292, E-TABM-321, ... (11 experiments)

369 groups
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-GEOD-7011, E-MEXP-2657, E-GEOD-20540, ... (8 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-MEXP-2069, E-GEOD-16363, ... (29 experiments)

Infection
studied in E-MEXP-561

Karyotype
studied in E-GEOD-7214

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-19703, E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, E-GEOD-17636 ... (5 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-19445, E-GEOD-19246

RNAi
studied in E-GEOD-12438, E-MEXP-101, E-MEXP-548, E-GEOD-3697, E-MEXP-1857, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728

sample status
studied in E-GEOD-30573

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-11428

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-TABM-276, E-GEOD-2748

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-89, E-TABM-43

Vehicle
studied in E-GEOD-5258

Processing time: 0.369 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM